Starpharma Prix / Ventes
Quel est le Prix / Ventes de Starpharma?
Le Prix / Ventes de Starpharma Holdings Limited est 22.31
Quelle est la définition de Prix / Ventes?
Le rapport prix / ventes est le prix des actions d'une entreprise par rapport à ses revenus.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Prix / Ventes des entreprises dans Health Care secteur sur ASX par rapport à Starpharma
Que fait Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Entreprises avec prix / ventes similaire à Starpharma
- Resources of Australia Ltd a Prix / Ventes de 22.18
- InnoCare Pharma a Prix / Ventes de 22.19
- Octopus Apollo VCT a Prix / Ventes de 22.19
- Evogene Ltd a Prix / Ventes de 22.21
- Scorpion Minerals a Prix / Ventes de 22.23
- Flexdeal Simfe S.A a Prix / Ventes de 22.31
- Starpharma a Prix / Ventes de 22.31
- Evergrande Health Industry a Prix / Ventes de 22.32
- Immuron a Prix / Ventes de 22.34
- Oxford Square Capital Corp a Prix / Ventes de 22.35
- Gritstone Bio Inc a Prix / Ventes de 22.37
- SFund International a Prix / Ventes de 22.53
- DL a Prix / Ventes de 22.58